Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 5-Azacytidine priming before the
conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an
effective treatment for high risk myeloid malignancies in complete remission (CR).